Triggered Surface Slips in the Salton Trough Associated with the 1999 Hector Mine, California, Earthquake

Surface fracturing occurred along the southern San Andreas, Superstition Hills, and Imperial faults in association with the 16 October 1999 (Mw 7.1) Hector Mine earthquake, making this at least the eighth time in the past 31 years that a regional earthquake has triggered slip along faults in the Salton Trough. Fractures associated with the event formed discontinuous breaks over a 39-km-long stretch of the San Andreas fault, from the Mecca Hills southeastward to Salt Creek and Durmid Hill, a distance from the epicenter of 107 to 139 km. Sense of slip was right lateral; only locally was there a minor (∼1 mm) vertical component of slip. Dextral slip ranged from 1 to 13 mm. Maximum slip values in 1999 and earlier triggered slips are most common in the central Mecca Hills. Field evidence indicates a transient opening as the Hector Mine seismic waves passed the southern San Andreas fault. Comparison of nearby strong-motion records indicates several periods of relative opening with passage of the Hector Mine seismic wave—a similar process may have contributed to the field evidence of a transient opening. Slip on the Superstition Hills fault extended at least 9 km, at a distance from the Hector Mine epicenter of about 188 to 196 km. This length of slip is a minimum value, because we saw fresh surface breakage extending farther northwest than our measurement sites. Sense of slip was right lateral; locally there was a minor (∼1 mm) vertical component of slip. Dextral slip ranged from 1 to 18 mm, with the largest amounts found distributed (or skewed) away from the Hector Mine earthquake source. Slip triggered on the Superstition Hills fault commonly is skewed away from the earthquake source, most notably in 1968, 1979, and 1999. Surface slip on the Imperial fault and within the Imperial Valley extended about 22 km, representing a distance from the Hector Mine epicenter of about 204 to 226 km. Sense of slip dominantly was right lateral; the right-lateral component of slip ranged from 1 to 19 mm. Locally there was a minor (∼1–2 mm) vertical component of slip; larger proportions of vertical slip (up to 10 mm) occurred in Mesquite basin, where scarps indicate long-term oblique-slip motion for this part of the Imperial fault. Slip triggered on the Imperial fault appears randomly distributed relative to location along the fault and source direction. Multiple surface slips, both primary and triggered slip, indicate that slip repeatedly is small at locations of structural complexity

Recommendations of the task force on public policy

This is the published version, reproduced here with permission from the publisher. This article is also available electronically from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741851/.The Task Force on Public Policy was established by the Association for Behavior Analysis to examine ways to encourage members to contribute to policymaking relevant to the public interest. Members discussed issues pertinent to this activity and summarized their discussion in a formal report.' Recommendations of the Task Force for conducting and disseminating policy research and for training, technical assistance, and other services supportive of behavior-analytic research in the public policy arena are presented here

Virologic Failures on Initial Boosted-PI Regimen Infrequently Possess Low-Level Variants with Major PI Resistance Mutations by Ultra-Deep Sequencing

It is unknown whether HIV-positive patients experiencing virologic failure (VF) on boosted-PI (PI/r) regimens without drug resistant mutations (DRM) by standard genotyping harbor low-level PI resistant variants. CASTLE compared the efficacy of atazanavir/ritonavir (ATV/r) with lopinavir/ritonavir (LPV/r), each in combination with TVD in ARV-naïve subjects.To determine if VF on an initial PI/r-based regimen possess low-level resistant variants that may affect a subsequent PI-containing regimen.Patients experiencing VF on a Tenofovir/Emtricitabine+PI/r regimen were evaluated by ultra deep sequencing (UDS) for mutations classified/weighted by Stanford HIVdb. Samples were evaluated for variants to 0.4% levels. 36 VF subjects were evaluated by UDS; 24 had UDS for PI and RT DRMs. Of these 24, 19 (79.2%) had any DRM by UDS. The most common UDS-detected DRM were NRTI in 18 subjects: M184V/I (11), TAMs(7) & K65R(4); PI DRMs were detected in 9 subjects: M46I/V(5), F53L(2), I50V(1), D30N(1), and N88S(1). The remaining 12 subjects, all with VLs<10,000, had protease gene UDS, and 4 had low-level PI DRMs: F53L(2), L76V(1), I54S(1), G73S(1). Overall, 3/36(8.3%) subjects had DRMs identified with Stanford-HIVdb weights >12 for ATV or LPV: N88S (at 0.43% level-mutational load 1,828) in 1 subject on ATV; I50V (0.44%-mutational load 110) and L76V (0.52%-mutational load 20) in 1 subject each, both on LPV. All VF samples remained phenotypically susceptible to the treatment PI/r.Among persons experiencing VF without PI DRMs with standard genotyping on an initial PI/r regimen, low-level variants possessing major PI DRMs were present in a minority of cases, occurred in isolation, and did not result in phenotypic resistance. NRTI DRMs were detected in a high proportion of subjects. These data suggest that PIs may remain effective in subjects experiencing VF on a PI/r-based regimen when PI DRMs are not detected by standard or UDS genotyping

Comparative Value of Four Measures of Retention in Expert Care in Predicting Clinical Outcomes and Health Care Utilization in HIV Patients

This study compared the ability of four measures of patient retention in HIV expert care to predict clinical outcomes. This retrospective study examined Veterans Health Administration (VHA) beneficiaries with HIV (ICD-9-CM codes 042 or V08) receiving expert care (defined as HIV-1 RNA viral load and CD4 cell count tests occurring within one week of each other) at VHA facilities from October 1, 2006, to September 30, 2008. Patients were ≥18 years old and continuous VHA users for at least 24 months after entry into expert care. Retention measures included: Annual Appointments (≥2 appointments annually at least 60 days apart), Missed Appointments (missed ≥25% of appointments), Infrequent Appointments (>6 months without an appointment), and Missed or Infrequent Appointments (missed ≥25% of appointments or >6 months without an appointment). Multivariable nominal logistic regression models were used to determine associations between retention measures and outcomes. Overall, 8,845 patients met study criteria. At baseline, 64% of patients were virologically suppressed and 37% had a CD4 cell count >500 cells/mm3. At 24 months, 82% were virologically suppressed and 46% had a CD4 cell count >500 cells/mm3. During follow-up, 13% progressed to AIDS, 48% visited the emergency department (ED), 28% were hospitalized, and 0.3% died. All four retention measures were associated with virologic suppression and antiretroviral therapy initiation at 24 months follow-up. Annual Appointments correlated positively with CD4 cell count >500 cells/mm3. Missed Appointments was predictive of all primary and secondary outcomes, including CD4 cell count ≤500 cells/mm3, progression to AIDS, ED visit, and hospitalization. Missed Appointments was the only measure to predict all primary and secondary outcomes. This finding could be useful to health care providers and public health organizations as they seek ways to optimize the health of HIV patients

1993 Progress Reports

The 1993 Progress Reports which contain Blueberry Tax Supported Weed Management and Pruning Project Reports, and CSRS Supported Weed Management and Pruning Project Reports, pertain to and report on research conducted in 1992. They were prepared for the Maine Wild Blueberry Commission and the University of Maine Wild Blueberry Advisory Committee by researchers at the University of Maine, Orono. Projects in this report include: Progress Reports 1. Effects of Irrigation on Low bush Blueberry Yield and Quality 2. Economics of Investing in Irrigation for Lowbush Blueberries 3. Diammonium Phosphate Study 4. Phosphorus Dose/Response Curve 5. Winter Injury Protection by Potassium 6. Multiple Cropping of Wild Stands 7. Effect of Boron on Lowbush Blueberry Fruit Set and Yield 8.Determination of Pesticide Residue Levels in Freshly Harvested and Processed Lowbush Blueberries 9. Effects of Calcium Salts and Citric Acids on the Quality of Canned Lowbush Blueberries- missing 10. Investigation of PreProcess Changes- missing 11. The Effect of Fertilization and Irrigation on Blueberry Fruit Control - missing 12. Pollination Ecology of Lowbush Blueberry in Maine 13. Control of Secondary Blueberry Pests 14. Control of Blueberry Maggot 15. Biology and Action Thresholds of Secondary Blueberry Pests 16. Cold-Hardiness of Native Lowbush Blueberries 17. Design, Fabrication, and Testing of an Experimental Sterilizer for Blueberry Fields 18. Canned Product Quality - Heat Resistant Molds 19. Sanitation for Disease Control Blueberry Tax Supported Weed Management and Pruning Project Reports 20. Evaluation of Postemergence Applications of Tribenuron Methyl for Bunchberry Control 21. Comparison of Poast and Select for Suppression of Bunchgrass 22. Effect of Time of Fall Pruning on Growth and Productivity of Blueberries. and Evaluation of Infrared Burner to Prune Blueberries 23. Evaluation of Velpar impregnated DAP for weed control 24. Thresholds of Dogbane and Bracken Fern for Mechanical and Chemical Control in Lowbush Blueberry Fields 25. Effect of Time and Rate of Application of Clopyralid for Control of Vetch in Lowbush Blueberries 26. Hexazinone Ground Water Survey 27. Composting Blueberry Processing Waste 28. Hexazinone Movement in a Blueberry Soil in Maine CSRS Supported Weed Management and Pruning Project Reports 29. Evaluation of the Suitability of Remote Sensing to Evaluate Plant Cover in Lowbush Blueberry Fields 30. Obstruction Removal in Lowbush Blueberry Fields 31. Evaluation of Pressurized Rope Wick Wick Master Wiper for Treating Weeds Growing Above Lowbush Blueberries 32. Evaluation of Infrared Burner for Weed Control 33. Blueberry Extension Education Program Base Miscellaneous 34. Comparison of N, NP, and NPK Fertilizers to Correct Nitrogen and Phosphorus Deficienc

1993-94 Progress Report

The 1993 edition of the Progress Reports was prepared for the Maine Wild Blueberry Commission and the University of Maine Wild Blueberry Advisory Committee by researchers at the University of Maine, Orono. Projects in this report include: 1. Effects of irrigation on lowbush blueberry yield and quality 2. The Economics of investigating irrigation for lowbush blueberries 3. Phosphorus dose/response curve 4. Winter injury protection by potassium 5. Multiple cropping of wild stands 6. Effect of Boron and Calcium on lowbush blueberry fruit set and yield 7. Comparison of N, NP, and NPK fertilizers to correct nitrogen and phosphorus deficiency 8. Determination of pesticide residue levels in freshly harvested and processed lowbush blueberries 9. Effects of calcium salts and citric acid on the quality of canned lowbush blueberries 10. Investigation of preprocess changes (chemical, microbiological, and/or physical) that can lead to the development of a simple and inexpensive method to measure preprocess berry spoilage 11. The effect of fertilization and irrigation in blueberry fruit quality 12. Pollination Ecology of lowbush blueberry in Maine 13. Current importance of insects in lowbush blueberry fields 14. Application of heat as a method of controlling secondary pest insects on lowbush blueberry: a feasibility study 15. Control of blueberry maggot 16. Control of secondary blueberry pest insects 17. Biology and action thresholds of secondary blueberry pest insects 18. Cold-hardiness of native lowbush blueberry 19. Design, fabrication, and testing of an experimental sterilizer for blueberry fields 20. Canned Product Quality--Heat-resistant molds 21. Sanitation for disease control 22. Evaluation of Velpar® impregnated DAP and Pronone® for weed control 23. Evaluation of postemergence applications of tribenuron methyl for bunchberry control 24. Evaluation of postemergence applications of a tank mix of tribenuron methyl and hexazinone for bunchberry control 25. Thresholds of dogbane and bracken fem by mechanical and chemical control in lowbush blueberry fields 26. Effect of time of application of clopyralid for control of vetch and effect on flowering in lowbush blueberries 27. Effect of time of fall pruning on growth and productivity of blueberries and evaluation of infrared burner to prune blueberries 28. Evaluation of infrared burner for selective seedling weed control 29. Evaluation of pressurized rope wick Wick Master wiper for treating weeds growing above lowbush blueberries 30. Blueberry Extension Education Program Base 31. Blueberry ICM program for Hancock County 32. Composting blueberry processing waste 33. Hexazinone ground water survey 34. Investigations of Lowbush Blueberry Fruit bud Cold-hardiness 35. Design, Fabrication, and Testing of an Experimental Sterilizer for Blueberry Field

Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens

Background: Hydroxyurea (HU) is an immunomodulatory agent that has been documented to enhance the antiretroviral activity of nucleoside reverse transcriptase inhibitors, such as abacavir (ABC) and didanosine (ddI), and would be expected to improve virologic efficacy. Methods: A 48-week, phase IV, multicenter, open-label, proof-of-concept clinical trial was conducted to evaluate second-line, protease inhibitor (PI)-sparing therapy with ABC/efavirenz (EFV)/ddl plus HU or without HU in HIV-infected subjects failing to achieve HIV-1 RNA ≤ 400 copies/mL after ≥ 16 weeks of treatment with lamivudine /zidovudine or lamivudine/stavudine, plus 1 or 2 Pls. Subjects were assigned to ABC (300 mg twice daily)/ EFV (600 mg once daily)/ ddI (400 mg once daily) plus HU (500 mg twice daily) (n = 30) or this regimen without HU (n = 24). Results: Baseline mean HIV-1 RNA was 3.86 log10 copies/mL and CD4+ cell count was 345 cells/mm3. A similar percentage of subjects in the non-HU arm (58%) and HU arm (53%) completed the study. Intent-to-treat: missing = failure analysis showed no differences in proportions of subjects in the non-HU and HU arms achieving undetectable plasma HIV-1 RNA levels at week 24 (&lt;400 copies/mL: 58% [14/24] vs 57% [17/30], P = 0.899; &lt;50 copies/mL (50% [12/24] vs 47% [14/30], P = 0.780). Median change from baseline in CD4+ cell count in the non-HU and HU arms at week 48 was +114 cells/mm3 and -63 cells/mm3 (P = 0.007), respectively. Both regimens were generally well tolerated, although more subjects in the HU arm withdrew prematurely from the study due to adverse events (23% vs 4%). Four cases of possible ABC-related hypersensitivity were observed. Conclusion: ABC/EFV/ddI was an effective and well-tolerated second-line regimen for nucleoside/PI-experienced HIV-infected subjects. The addition of HU blunted the CD4+ cell response, did not appear to enhance antiviral activity, and resulted in more treatment-limiting adverse events

Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-Naïve Subjects in the CASTLE Study

CASTLE compared the efficacy of atazanavir/ritonavir with lopinavir/ritonavir, each in combination with tenofovir-emtricitabine in ARV-naïve subjects from 5 continents.Determine the baseline rate and clinical significance of TDR mutations using ultra-deep sequencing (UDS) in ARV-naïve subjects in CASTLE.A case control study was performed on baseline samples for all 53 subjects with virologic failures (VF) at Week 48 and 95 subjects with virologic successes (VS) randomly selected and matched by CD4 count and viral load. UDS was performed using 454 Life Sciences/Roche technology.Of 148 samples, 141 had successful UDS (86 subtype B, 55 non-B subtypes). Overall, 30.5% of subjects had a TDR mutation at baseline; 15.6% only had TDR(s) at <20% of the viral population. There was no difference in the rate of TDRs by B (30.2%) or non-B subtypes (30.9%). VF (51) and VS (90) had similar rates of any TDRs (25.5% vs. 33.3%), NNRTI TDRs (11.1% vs.11.8%) and NRTI TDRs (24.4% vs. 25.5%). Of 9 (6.4%) subjects with M184V/I (7 at <20% levels), 6 experienced VF. 16 (11.3%) subjects had multiple TAMs, and 7 experienced VF. 3 (2.1%) subjects had both multiple TAMs+M184V, and all experienced VF. Of 14 (9.9%) subjects with PI TDRs (11 at <20% levels): only 1 experienced virologic failure. The majority of PI TDRs were found in isolation (e.g. 46I) at <20% levels, and had low resistance algorithm scores.Among a representative sample of ARV-naïve subjects in CASTLE, TDR mutations were common (30.5%); B and non-B subtypes had similar rates of TDRs. Subjects with multiple PI TDRs were infrequent. Overall, TDRs did not affect virologic response for subjects on a boosted PI by week 48; however, a small subset of subjects with extensive NRTI backbone TDR patterns experienced virologic failure

No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database

ObjectiveTo assess the potential association of selected antiretrovirals (ARVs), including efavirenz, with suicidality.DesignRetrospective analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS), by performing a Multi-Item Gamma Poisson Shrinker (MGPS) disproportionality analysis.MethodsMGPS disproportionality analysis, a technique to identify associations between drugs and adverse events, was performed using cumulative data from the FAERS database collected up to August 2012. This method yields an Empirical Bayesian Geometric Mean score and corresponding 90% confidence interval (EB05, EB95). EB05 scores ≥2 were pre-defined as a signal for a potential drug-event association. The FAERS database includes spontaneous adverse-event reports from consumers and healthcare professionals. All FAERS reports of suicidality (including suicidal ideation, suicide attempt and completed suicide or a composite of these) in patients taking efavirenz (as single agent or in fixed-dose combination), atazanavir, darunavir, etravirine, nevirapine and raltegravir were identified. A number of parallel analyses were performed to assess the validity of the methodology: fluoxetine and sertraline, antidepressants with a known association with suicidality, and raltegravir, an ARV with rhabdomyolysis and myopathy listed as “uncommon” events in the US-prescribing information.ResultsA total of 29,856 adverse event reports were identified among patients receiving efavirenz, atazanavir, darunavir, etravirine, nevirapine and raltegravir, of which 457 were reports of suicidality events. EB05 scores observed for the composite suicidality term for efavirenz (EB05=0.796), and other ARVs (EB05=0.279–0.368), were below the pre-defined threshold. Fluoxetine and sertraline gave EB05 scores for suicidality >2. Raltegravir gave EB05 scores >2 for myopathy and rhabdomyolysis.ConclusionsThe pre-determined threshold for signals for suicidality, including suicidal ideation, suicide attempt, completed suicide and a composite suicidality endpoint, was not exceeded for efavirenz and other ARVs in this analysis. Efavirenz has been associated with suicidality in clinical trials. Further studies that adjust for confounding factors are needed to better understand any potential association with ARVs and suicidality